Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers

OBJECTIVE: This phase I study of ZYAN1 was conducted to evaluate the safety, tolerability, and pharmacokinetics following oral administration in healthy volunteers. METHODS: The study was a randomized, double-blind, placebo-controlled phase I study carried out in two parts in addition to a third par...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Pharmacokinet
Main Authors: Kansagra, Kevinkumar A., Parmar, Deven, Jani, Rajendra H., Srinivas, Nuggehally R., Lickliter, Jason, Patel, Harilal V., Parikh, Devang P., Heading, Heather, Patel, Hardik B., Gupta, Rahul J., Shah, Chintan Y., Patel, Maulik R., Dholakia, Vyom N., Sukhadiya, Raghav, Jain, Mukul R., Parmar, Krupi V., Barot, Kinjal
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2017
Assuntos:
Original Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5766731/
https://ncbi.nlm.nih.gov/pubmed/28508936
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-017-0551-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados